Abeona Therapeutics (ABEO) News Today $6.16 -0.08 (-1.28%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.28 +0.12 (+1.93%) As of 06/13/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Abeona Therapeutics Inc (NASDAQ:ABEO) Receives Average Recommendation of "Buy" from AnalystsAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) has received a consensus recommendation of "Buy" from the five research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average twelve-month price objective amoJune 13 at 4:25 AM | marketbeat.comCantor Fitzgerald Weighs in on ABEO FY2026 EarningsJune 11, 2025 | americanbankingnews.comBrokers Offer Predictions for ABEO FY2026 EarningsAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Abeona Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that theJune 10, 2025 | marketbeat.comWellington Management Group LLP Invests $520,000 in Abeona Therapeutics Inc (NASDAQ:ABEO)Wellington Management Group LLP acquired a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 93,289 shares of the biopharmaceutical company's stock, valuedJune 8, 2025 | marketbeat.comBrendan M. O'malley Sells 10,470 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) StockJune 7, 2025 | insidertrades.comAbeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O'malley Sells 10,470 SharesAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) SVP Brendan M. O'malley sold 10,470 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $6.76, for a total value of $70,777.20. Following the completion of the sale, the senior vice president now owns 378,245 shares of the company's stock, valued at $2,556,936.20. The trade was a 2.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.June 6, 2025 | marketbeat.comInsider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Sells 17,795 Shares of StockAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CFO Joseph Walter Vazzano sold 17,795 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $120,294.20. Following the sale, the chief financial officer now directly owns 491,246 shares in the company, valued at $3,320,822.96. This trade represents a 3.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.June 6, 2025 | marketbeat.comVishwas Seshadri Sells 50,676 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) StockAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 50,676 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $6.76, for a total transaction of $342,569.76. Following the completion of the sale, the chief executive officer now directly owns 1,303,761 shares of the company's stock, valued at $8,813,424.36. This represents a 3.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.June 6, 2025 | marketbeat.comAbeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)June 5, 2025 | seekingalpha.comOppenheimer assumes coverage on Abeona Therapeutics stockJune 4, 2025 | uk.investing.comAbeona Therapeutics (NASDAQ:ABEO) Now Covered by Analysts at OppenheimerOppenheimer assumed coverage on Abeona Therapeutics in a report on Monday. They issued an "outperform" rating and a $19.00 price objective on the stock.June 2, 2025 | marketbeat.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comAbeona Therapeutics® to Present at the Jefferies Global Healthcare ConferenceMay 30, 2025 | finance.yahoo.comAbeona Therapeutics® to Present at the Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comAbeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $12,760.00 in StockAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 2,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $6.38, for a total transaction of $12,760.00. Following the transaction, the director now directly owns 90,435 shares of the company's stock, valued at $576,975.30. The trade was a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.May 29, 2025 | marketbeat.comMark Alvino Sells 2,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) StockMay 28, 2025 | insidertrades.comJane Street Group LLC Purchases 118,262 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)Jane Street Group LLC raised its position in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 894.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 131,478 shares of the biopharmaceutical company's stock after acquiring an additionaMay 27, 2025 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Stock Holdings Reduced by Millennium Management LLCMillennium Management LLC cut its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 8.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,117,169 shares of the biopharmaceMay 26, 2025 | marketbeat.comFY2025 Earnings Forecast for ABEO Issued By Zacks Small CapAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities researchers at Zacks Small Cap raised their FY2025 earnings estimates for Abeona Therapeutics in a report issued on Monday, May 19th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($0.64)May 24, 2025 | marketbeat.comFY2025 EPS Estimates for ABEO Lifted by Cantor FitzgeraldAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Abeona Therapeutics in a research report issued on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical companyMay 23, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for ABEO EarningsAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for Abeona Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.May 23, 2025 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) is Western Standard LLC's 3rd Largest PositionWestern Standard LLC increased its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,084,418 shares of the biopharmaceutical company's stock after purchasing anMay 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes $362,000 Position in Abeona Therapeutics Inc (NASDAQ:ABEO)OMERS ADMINISTRATION Corp bought a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 65,045 shares of the biopharmaceutical company's stock, valued at approxiMay 22, 2025 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Receives Consensus Recommendation of "Buy" from BrokeragesAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) has been assigned a consensus recommendation of "Buy" from the four ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 12-monthMay 21, 2025 | marketbeat.comABEO: Sells Priority Review Voucher for $155 Million…May 20, 2025 | finance.yahoo.comAbeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comMark Alvino Sells 8,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) StockMay 17, 2025 | insidertrades.comAbeona Therapeutics Reports Improved Financial PerformanceMay 17, 2025 | tipranks.comInsider Selling: Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO)May 16, 2025 | gurufocus.comAbeona Therapeutics’ Earnings Call Highlights ZEVASKYN SuccessMay 16, 2025 | tipranks.comAbeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runwayMay 16, 2025 | msn.comAbeona Therapeutics (ABEO) Expected to Announce Earnings on WednesdayAbeona Therapeutics (NASDAQ:ABEO) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-abeona-therapeutics-inc-stock/)May 16, 2025 | marketbeat.comAbeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comAbeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate UpdatesMay 15, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Makes New Investment in Abeona Therapeutics Inc (NASDAQ:ABEO)Schonfeld Strategic Advisors LLC acquired a new position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 61,266 shares of the biopharmaMay 15, 2025 | marketbeat.comAbeona Therapeutics Sees Unusually High Options Volume (NASDAQ:ABEO)Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the recipient of some unusual options trading on Monday. Investors acquired 5,499 call options on the stock. This is an increase of 657% compared to the average daily volume of 726 call options.May 14, 2025 | marketbeat.comUPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin DisorderMay 14, 2025 | globenewswire.comAbeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNâ„¢ Gene Therapy to Treat Wounds in Painful Skin DisorderMay 14, 2025 | globenewswire.comAbeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin DisorderMay 14, 2025 | globenewswire.comAbeona secures cash runway with $155m priority review voucher saleMay 14, 2025 | msn.com1CAPR : A Look Ahead: Capricor Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comA Preview Of Lexicon Pharmaceuticals's EarningsMay 12, 2025 | benzinga.comAbeona Therapeutics Inc.: Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 MillionMay 12, 2025 | finanznachrichten.deAbeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 MillionMay 12, 2025 | globenewswire.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 | globenewswire.comRenaissance Technologies LLC Has $497,000 Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)Renaissance Technologies LLC decreased its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 33.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,237 shares of thMay 6, 2025 | marketbeat.comABEO FY2025 EPS Forecast Boosted by Cantor FitzgeraldAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings estimates for Abeona Therapeutics in a report released on Wednesday, April 30th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will posMay 4, 2025 | marketbeat.comQ3 EPS Estimate for Abeona Therapeutics Boosted by AnalystAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Research analysts at Zacks Small Cap raised their Q3 2025 earnings per share estimates for Abeona Therapeutics in a research report issued on Wednesday, April 30th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical coMay 4, 2025 | marketbeat.comQ2 EPS Forecast for Abeona Therapeutics Decreased by AnalystAbeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Abeona Therapeutics in a research report issued to clients and investors on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now anticipatMay 4, 2025 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Shares Acquired by 683 Capital Management LLC683 Capital Management LLC boosted its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 17.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 791,845 shares of the biopharmaceutiMay 4, 2025 | marketbeat.com Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Media Mentions By Week ABEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABEO News Sentiment▼1.260.89▲Average Medical News Sentiment ABEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABEO Articles This Week▼73▲ABEO Articles Average Week Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MannKind News Travere Therapeutics News Qilian International Holding Group News Amphastar Pharmaceuticals News Dynavax Technologies News Calliditas Therapeutics AB (publ) News Pacira BioSciences News Structure Therapeutics News Harrow News Aurinia Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABEO) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
